Skip to main content
×
×
Home

Treatment for mild cognitive impairment: systematic review

  • Claudia Cooper (a1), Ryan Li (a1), Constantine Lyketsos (a2) and Gill Livingston (a1)
Abstract
Background

More people are presenting with mild cognitive impairment (MCI), frequently a precursor to dementia, but we do not know how to reduce deterioration.

Aims

To systematically review randomised controlled trials (RCTs) evaluating the effects of any intervention for MCI on cognitive, neuropsychiatric, functional, global outcomes, life quality or incident dementia.

Method

We reviewed 41 studies fitting predetermined criteria, assessed validity using a checklist, calculated standardised outcomes and prioritised primary outcome findings in placebo-controlled studies.

Results

The strongest evidence was that cholinesterase inhibitors did not reduce incident dementia. Cognition improved in single trials of: a heterogeneous psychological group intervention over 6 months; piribedil, a dopamine agonist over 3 months; and donepezil over 48 weeks. Nicotine improved attention over 6 months. There was equivocal evidence that Huannao Yicong improved cognition and social functioning.

Conclusions

There was no replicated evidence that any intervention was effective. Cholinesterase inhibitors and rofecoxib are ineffective in preventing dementia. Further good-quality RCTs are needed and preliminary evidence suggests these should include trials of psychological group interventions and piribedil.

Declarations of interest

C.L. has received grant support (research or continuing medical education) from NIMH, NIA, Associated Jewish Federation of Baltimore, Weinberg Foundation, Forest, GlaxoSmithKline, Eisai, Pfizer, AstraZeneca, Lilly, Ortho-McNeil, Bristol-Myers Squibb, Novartis, National Football League (NFL), Elan, Functional Neuromodulation; and has been a consultant/advisor to AstraZeneca, GlaxoSmithKline, Eisai, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Lilly, Pfizer, Genentech, Elan, NFL Players Association, NFL Benefits Office, Avanir, Zinfandel, Bristol-Myers Squibb; and received honorarium or travel support from Pfizer, Forest, GlaxoSmithKline, Health Monitor.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Treatment for mild cognitive impairment: systematic review
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Treatment for mild cognitive impairment: systematic review
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Treatment for mild cognitive impairment: systematic review
      Available formats
      ×
Copyright
Corresponding author
Claudia Cooper, Mental Health Sciences Unit, University College London, Holborn Union Building, Highgate Hill, London N19 5LW, UK. Email: c.cooper@ucl.ac.uk
References
Hide All
1 Petersen, RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256: 183–94.
2 Lopez, OL, Kuller, LH, Becker, JT, Dulberg, C., Sweet, RA, Gach, HM et al. Incidence of dementia in mild cognitive impairment in the cardiovascular health study cognition study. Arch Neurol 2007; 64: 416–20.
3 Tschanz, JT, Welsh-Bohmer, KA, Lyketsos, CG, Corcoran, C., Green, RC, Hayden, K., et al. Conversion to dementia from mild cognitive disorder – the Cache County Study. Neurology 2006; 67: 229–34.
4 National Institute for Health and Clinical Excellence. Dementia: Supporting People with Dementia and their Carers in Health and Social Care. Clinical Guideline 42. NICE, 2006.
5 Jorm, AF, Korten, AE, Henderson, AS. The prevalence of dementia – a quantitative integration of the literature. Acta Psychiatr Scand 1987; 76: 465–79.
6 Raschetti, R., Albanese, E., Vanacore, N., Maggini, M. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med 2007; 4: e338.
7 Birks, J., Flicker, L. Donepezil for mild cognitive impairment. Cochrane Database Syst Rev 2006; 3: CD006104.
8 Loy, C., Schneider, L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev 2006; 1: CD001747.
9 Martin, M., Clare, L., Altgassen, AM, Cameron, MH, Zehnder, F. Cognition-based interventions for healthy older people and people with mild cognitive impairment. Cochrane Database Syst Rev 2011; 1: CD006220.
10 Gates, NJ, Sachdev, PS, Fiatarone Singh, MA, Valenzuela, M. Cognitive and memory training in adults at risk of dementia: a systematic review. BMC Geriatr 2011; 11: 55.
11 Jean, L., Bergeron, ME, Thivierge, S., Simard, M. Cognitive intervention programs for individuals with mild cognitive impairment: systematic review of the literature. Am J Geriatr Psychiatry 2010; 18: 281–96.
12 Simon, SS, Yokomizo, JE, Bottino, CM. Cognitive intervention in amnestic mild cognitive impairment: a systematic review. Neurosci Biobehav Rev 2012; 36: 1163–78.
13 Stott, J., Spector, A. A review of the effectiveness of memory interventions in mild cognitive impairment (MCI). Int Psychogeriatr 2011; 23: 526–38.
14 Unverzagt, FW, Kasten, L., Johnson, KE, Rebok, GW, Marsiske, M., Koepke, KM, et al. Effect of memory impairment on training outcomes in ACTIVE. J Internat Neuropsychol Soc 2007; 13: 953–60.
15 Doody, RS, Ferris, SH, Salloway, S., Sun, Y., Goldman, R., Watkins, WE, et al. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology 2009; 72: 1555–61.
16 StatsDirect. Stats Direct Statistical Software. StatsDirect, 2012.
17 Baker, LD, Frank, LL, Foster-Schubert, K., Green, PS, Wilkinson, CW, McTiernan, A., et al. Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch Neurol 2010; 67: 71–9.
18 Barnes, DE, Yaffe, K., Belfor, N., Jagust, WJ, DeCarli, C., Reed, BR, et al. Computer-based cognitive training for mild cognitive impairment: results from a pilot randomized, controlled trial. Alzheimer Dis Assoc Disord 2009; 23: 205–10.
19 Buschert, VC, Friese, U., Teipel, SJ, Schneider, P., Merensky, W., Rujescu, D., et al. Effects of a newly developed cognitive intervention in amnestic mild cognitive impairment and mild Alzheimer's disease: a pilot study. J Alzheimers Dis 2011; 25: 679–94.
20 Kinsella, GJ, Mullaly, E., Rand, E., Ong, B., Burton, C., Price, S., et al. Early intervention for mild cognitive impairment: a randomised controlled trial. J Neurol Neurosurg Psychiatry 2009; 80: 730–6.
21 Newhouse, P., Kellar, K., Aisen, P., White, H., Wesnes, K., Coderre, E., et al. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology 2012; 78: 91101.
22 Koontz, J., Baskys, A. Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: a double-blind placebo-controlled study. Am J Alzheimers Dis Other Demen 2005; 20: 295302.
23 Nagaraja, D., Jayashree, S. Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. Am J Psychiatry 2001; 158: 1517–9.
24 Troyer, AK, Murphy, KJ, Anderson, ND, Moscovitch, M., Craik, FI. Changing everyday memory behaviour in amnestic mild cognitive impairment: a randomised controlled trial. Neuropsychol Rehabil 2008; 18: 6588.
25 Zhao, MX, Dong, ZH, Yu, ZH, Xiao, SY, Li, YM. Effects of Ginkgo biloba extract in improving episodic memory of patients with mild cognitive impairment: a randomized controlled trial [in Chinese]. Zhong Xi Yi Jie He Xue Bao 2012; 10: 628–34.
26 Busse, AL, Filho, JW, Magaldi, RM, Coelho, VA, Melo, AC, Betoni, RA, et al. Effects of resistance training exercise on cognitive performance in elderly individuals with memory impairment: results of a controlled trial. Einstein 2008; 6: 402–7.
27 Pelton, GH, Harper, OL, Tabert, MH, Sackeim, HA, Scarmeas, N., Roose, SP, et al. Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: a pilot study. Int J Geriatr Psychiatry 2008; 23: 670–6.
28 Li, H., Yao, MJ, Zhao, WM, Guan, J., Cai, LL, Cui, L. A randomized, controlled, double-blind trial of Huannao Yicong capsule in senile patients with mild cognitive impairment [in Chinese]. Zhong Xi Yi Jie He Xue Bao 2008; 6: 2531.
29 Chiu, CC, Su, KP, Cheng, TC, Liu, HC, Chang, CJ, Dewey, ME, et al. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1538–44.
30 de Jager, CA, Oulhaj, A., Jacoby, R., Refsum, H., Smith, AD. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. Int J Geriatr Psychiatry 2012; 27: 592600.
31 Feldman, HH, Ferris, S., Winblad, B., Sfikas, N., Mancione, L., He, Y., et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007; 6: 501–12.
32 Krikorian, R., Nash, TA, Shidler, MD, Shukitt-Hale, B., Joseph, JA. Concord grape juice supplementation improves memory function in older adults with mild cognitive impairment. Br J Nutr 2010; 103: 730–4.
33 Park, SK, Jung, IC, Lee, WK, Lee, YS, Park, HK, Go, HJ, et al. A combination of green tea extract and I-theanine improves memory and attention in subjects with mild cognitive impairment: a double-blind placebo-controlled study. J Med Food 2011; 14: 334–43.
34 Sinn, N., Milte, CM, Street, SJ, Buckley, JD, Coates, AM, Petkov, J., et al. Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. Br J Nutr 2012; 107: 1682–93.
35 DeKosky, ST, Williamson, JD, Fitzpatrick, AL, Kronmal, RA, Ives, DG, Saxton, JA, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 2008; 300: 2253–62.
36 Fu, H., Wang, XM, Liu, GX. Effects of modified Wuzi Yanzong Granule on memory ability and volume of hippocampus measured by MRI in patients with mild cognitive impairment [in Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi 2006; 26: 1066–9.
37 Tian, JZ, Zhu, AH, Zhong, J. A follow-up study on a randomized, single-blind control of King's Brain pills in treatment of memory disorder in elderly people with MCI in a Beijing community [in Chinese]. Zhongguo Zhong Yao Za Zhi 2003; 28: 987–91.
38 van Uffelen, JG, Chinapaw, MJ, van, MW, Hopman-Rock, M. Walking or vitamin B for cognition in older adults with mild cognitive impairment? A randomised controlled trial. Br J Sports Med 2008; 42: 344–51.
39 Luijpen, MW, Swaab, DF, Sergeant, JA, Scherder, EJ. Effects of transcutaneous electrical nerve stimulation (TENS) on self-efficacy and mood in elderly with mild cognitive impairment. Neurorehabil Neural Repair 2004; 18: 166–75.
40 Rondanelli, M., Opizzi, A., Faliva, M., Mozzoni, M., Antoniello, N., Cazzola, R., et al. Effects of a diet integration with an oily emulsion of DHA-phospholipids containing melatonin and tryptophan in elderly patients suffering from mild cognitive impairment. Nutr Neurosci 2012; 15: 4654.
41 Scherder, EJ, Van, PJ, Deijen, JB, Van Der Knokke, S., Orlebeke, JF, Burgers, I., et al. Physical activity and executive functions in the elderly with mild cognitive impairment. Aging Ment Health 2005; 9: 272–80.
42 Suzuki, T., Shimada, H., Makizako, H., Doi, T., Yoshida, D., Tsutsumimoto, K., et al. Effects of multicomponent exercise on cognitive function in older adults with amnestic mild cognitive impairment: a randomized controlled trial. BMC Neurology 2012; 12: 128.
43 Mowla, A., Mosavinasab, M., Pani, A. Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial. J Clin Psychopharmacol 2007; 27: 6770.
44 Gomez-Isla, T., Blesa, R., Boada, M., Clarimon, J., Del, ST, Domenech, G., et al. A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study. Alzheimer Dis Assoc Disord 2008; 22: 21–9.
45 Petersen, RC, Thomas, RG, Grundman, M., Bennett, D., Doody, R., Ferris, S., et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352: 2379–88.
46 Rapp, S., Brenes, G., Marsh, AP. Memory enhancement training for older adults with mild cognitive impairment: a preliminary study. Aging Ment Health 2002; 6: 511.
47 Rozzini, L., Costardi, D., Chilovi, BV, Franzoni, S., Trabucchi, M., Padovani, A. Efficacy of cognitive rehabilitation in patients with mild cognitive impairment treated with cholinesterase inhibitors. Int J Geriatr Psychiatry 2007; 22: 356–60.
48 Salloway, S., Ferris, S., Kluger, A., Goldman, R., Griesing, T., Kumar, D., et al. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology 2004; 63: 651–7.
49 Thal, LJ, Ferris, SH, Kirby, L., Block, GA, Lines, CR, Yuen, E., et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005; 30: 1204–15.
50 Zhou, RQ, Lin, SM, Yuan, Q. Clinical study on effect of Shenyin Oral Liquid in treating mild cognitive impairment [in Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi 2007; 27: 793–5.
51 Winblad, B., Gauthier, S., Scinto, L., Feldman, H., Wilcock, GK, Truyen, L. et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008; 70: 2024–35.
52 Ferris, S., Schneider, L., Farmer, M., Kay, G., Crook, T. A double-blind, placebo-controlled trial of memantine in age-associated memory impairment (memantine in AAMI). Int J Geriatr Psychiatry 2007; 22: 448–55.
53 Jean, L., Simard, M., Wiederkehr, S., Bergeron, ME, Turgeon, Y., Hudon, C., et al. Efficacy of a cognitive training programme for mild cognitive impairment: results of a randomised controlled study. Neuropsychol Rehabil 2010; 20: 377405.
54 van Uffelen, JG, Chin, APMJ, Hopman-Rock, M., van Mechelen, W. The effect of walking and vitamin B supplementation on quality of life in community-dwelling adults with mild cognitive impairment: a randomized, controlled trial. Qual Life Res 2007; 16: 1137–46.
55 Finn, M., McDonald, S. Computerised cognitive training for older persons with mild cognitive impairment: a pilot study using a randomised controlled trial design. Brain Impair 2011; 12: 187–99.
56 Birks, J., Evans, JG. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2009; 1: CD003120.
57 Snitz, BE, O'Meara, ES, Carlson, MC, Arnold, AM, Ives, DG, Rapp, SR, et al. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA 2009; 302: 2663–70.
58 Weggen, S., Eriksen, JL, Das, P., Sagi, SA, Wang, R., Pietrzik, CU, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001; 414: 212–6.
59 Forlenza, OV, Diniz, BS, Radanovic, M., Santos, FS, Talib, LL, Gattaz, WF. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry 2011; 198: 351–6.
60 Busse, A., Angermeyer, MC, Riedel-Heller, SG. Progression of mild cognitive impairment to dementia: a challenge to current thinking. Br J Psychiatry 2006; 189: 399404.
61 Schneider, LS. The potential and limits for clinical trials for early Alzheimer's disease and some recommendations. J Nutr Health Aging 2010; 14: 295–8.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×
Type Description Title
PDF
Supplementary materials

Cooper et al. supplementary material
Supplementary Table S1-S2

 PDF (63 KB)
63 KB

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 65 *
Loading metrics...

Abstract views

Total abstract views: 227 *
Loading metrics...

* Views captured on Cambridge Core between 3rd January 2018 - 23rd April 2018. This data will be updated every 24 hours.

Treatment for mild cognitive impairment: systematic review

  • Claudia Cooper (a1), Ryan Li (a1), Constantine Lyketsos (a2) and Gill Livingston (a1)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *